Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Fuji
Moodys
AstraZeneca
Daiichi Sankyo
Merck
Healthtrust
Harvard Business School
Queensland Health

Generated: July 15, 2018

DrugPatentWatch Database Preview

Loxapine hydrochloride - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic sources for loxapine hydrochloride and what is the scope of loxapine hydrochloride patent protection?

Loxapine hydrochloride
is the generic ingredient in two branded drugs marketed by Actavis Labs Ut Inc and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

There are eight drug master file entries for loxapine hydrochloride.
Summary for loxapine hydrochloride
Synonyms for loxapine hydrochloride
1977-10-2 (Parent)
2-Chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazepine monohydrochloride
376MYL4MAL
54810-23-0
8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine hydrochloride
AC1L2G3B
CHEMBL1201060
D08148
Desconex (TN)
Dibenz(b,f)(1,4)oxazepine, 2-chloro-11-(4-methyl-1-piperazinyl)-, monohydrochloride
DTXSID70203304
Loxapine HCl
Loxapine monohydrochloride
LOXITANE C
LS-186470
SCHEMBL41625
UNII-376MYL4MAL

US Patents and Regulatory Information for loxapine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Actavis Labs Ut Inc LOXITANE IM loxapine hydrochloride INJECTABLE;INJECTION 018039-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Actavis Labs Ut Inc LOXITANE C loxapine hydrochloride CONCENTRATE;ORAL 017658-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for loxapine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Actavis Labs Ut Inc LOXITANE C loxapine hydrochloride CONCENTRATE;ORAL 017658-001 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Actavis Labs Ut Inc LOXITANE IM loxapine hydrochloride INJECTABLE;INJECTION 018039-001 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Actavis Labs Ut Inc LOXITANE C loxapine hydrochloride CONCENTRATE;ORAL 017658-001 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Chubb
Mallinckrodt
Healthtrust
Deloitte
Medtronic
Fuji
Julphar
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.